PMID- 35865469
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220723
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - CircRNA-Associated CeRNAs Regulatory Axes in Retinoblastoma: A Systematic Scoping 
      Review.
PG  - 910470
LID - 10.3389/fonc.2022.910470 [doi]
LID - 910470
AB  - Retinoblastoma (RB) is one of the most common childhood cancers caused by RB gene 
      mutations (tumor suppressor gene in various patients). A better understanding of 
      molecular pathways and the development of new diagnostic approaches may lead to 
      better treatment for RB patients. The number of studies on ceRNA axes is 
      increasing, emphasizing the significance of these axes in RB. Circular RNAs 
      (circRNAs) play a vital role in competing endogenous RNA (ceRNA) regulatory axes 
      by sponging microRNAs and regulating gene expression. Because of the broadness of 
      ceRNA interaction networks, they may assist in investigating treatment targets in 
      RB. This study conducted a systematic scoping review to evaluate verified loops 
      of ceRNA in RB, focusing on the ceRNA axis and its relationship to circRNAs. This 
      scoping review was carried out using a six-step strategy and the Prisma 
      guideline, and it involved systematically searching the publications of seven 
      databases. Out of 363 records, sixteen articles were entirely consistent with the 
      defined inclusion criteria and were summarized in the relevant table. The 
      majority of the studies focused on the circRNAs circ_0000527, circ_0000034, and 
      circTET1, with approximately two-fifths of the studies focusing on a single 
      circRNA. Understanding the many features of this regulatory structure may help 
      elucidate RB's unknown causative factors and provide novel molecular potential 
      therapeutic targets and medical fields.
CI  - Copyright (c) 2022 Asadi, Moslehian, Sabaie, Sharifi-Bonab, Hakimi, Hussen, Taheri, 
      Rakhshan and Rezazadeh.
FAU - Asadi, Mohammad Reza
AU  - Asadi MR
AD  - Clinical Research Development Unit of Tabriz Valiasr Hospital, Tabriz University 
      of Medical Sciences, Tabriz, Iran.
FAU - Moslehian, Marziyeh Sadat
AU  - Moslehian MS
AD  - Clinical Research Development Unit of Tabriz Valiasr Hospital, Tabriz University 
      of Medical Sciences, Tabriz, Iran.
FAU - Sabaie, Hani
AU  - Sabaie H
AD  - Clinical Research Development Unit of Tabriz Valiasr Hospital, Tabriz University 
      of Medical Sciences, Tabriz, Iran.
FAU - Sharifi-Bonab, Mirmohsen
AU  - Sharifi-Bonab M
AD  - Clinical Research Development Unit of Tabriz Valiasr Hospital, Tabriz University 
      of Medical Sciences, Tabriz, Iran.
FAU - Hakimi, Parvin
AU  - Hakimi P
AD  - Woman's Reproductive Health Research Center, Tabriz University of medical 
      sciences, Tabriz, Iran.
FAU - Hussen, Bashdar Mahmud
AU  - Hussen BM
AD  - Department of Pharmacognosy, College of Pharmacy, Hawler Medical University, 
      Erbil, Iraq.
AD  - Center of Research and Strategic Studies, Lebanese French University, Erbil, 
      Iraq.
FAU - Taheri, Mohammad
AU  - Taheri M
AD  - Urology and Nephrology Research Center, Shahid Beheshti University of Medical 
      Sciences, Tehran, Iran.
AD  - Institute of Human Genetics, Jena University Hospital, Jena, Germany.
FAU - Rakhshan, Azadeh
AU  - Rakhshan A
AD  - Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, 
      Iran.
FAU - Rezazadeh, Maryam
AU  - Rezazadeh M
AD  - Clinical Research Development Unit of Tabriz Valiasr Hospital, Tabriz University 
      of Medical Sciences, Tabriz, Iran.
AD  - Woman's Reproductive Health Research Center, Tabriz University of medical 
      sciences, Tabriz, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220705
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9294360
OTO - NOTNLM
OT  - CeRNA
OT  - circTET1
OT  - circ_0000034
OT  - circ_0000527
OT  - circular RNA
OT  - retinoblastoma
OT  - sponge
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/07/23 06:00
MHDA- 2022/07/23 06:01
PMCR- 2022/01/01
CRDT- 2022/07/22 02:28
PHST- 2022/04/01 00:00 [received]
PHST- 2022/06/10 00:00 [accepted]
PHST- 2022/07/22 02:28 [entrez]
PHST- 2022/07/23 06:00 [pubmed]
PHST- 2022/07/23 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.910470 [doi]
PST - epublish
SO  - Front Oncol. 2022 Jul 5;12:910470. doi: 10.3389/fonc.2022.910470. eCollection 
      2022.